

Levente Szalardy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2914444/publications.pdf>

Version: 2024-02-01

26
papers

1,026
citations

687363

13
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

1950
citing authors

#	ARTICLE	IF	CITATIONS
1	Kynurenines in the CNS: recent advances and new questions. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 64-82.	46.4	480
2	PACAP and its role in primary headaches. <i>Journal of Headache and Pain</i> , 2018, 19, 21.	6.0	78
3	Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 523-547.	2.6	75
4	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S177-S187.	2.6	64
5	Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis—osteopontin as a potential marker of clinical severity. <i>Journal of the Neurological Sciences</i> , 2013, 331, 38-42.	0.6	52
6	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 573-595.	2.9	38
7	Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1797-806.	2.1	25
8	Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. <i>Neuroscience Letters</i> , 2013, 554, 131-134.	2.1	22
9	Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-19.	4.0	22
10	Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 132, 115-124.	2.9	20
11	Neuropathology of Partial PGC-1 β Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. <i>Neurodegenerative Diseases</i> , 2013, 12, 177-188.	1.4	17
12	Investigational α -synuclein aggregation inhibitors: hope for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1281-1294.	4.1	17
13	Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis—Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. <i>International Journal of Molecular Sciences</i> , 2019, 20, 426.	4.1	16
14	Histopathological comparison of Kearns-Sayre syndrome and PGC-1 β -deficient mice suggests a novel concept for vacuole formation in mitochondrial encephalopathy. <i>Folia Neuropathologica</i> , 2016, 1, 9-22.	1.2	15
15	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012–2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 815-832.	5.0	14
16	Lack of age-related clinical progression in PGC-1 β -deficient mice—implications for mitochondrial encephalopathies. <i>Behavioural Brain Research</i> , 2016, 313, 272-281.	2.2	11
17	Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy. <i>Journal of Neural Transmission</i> , 2020, 127, 963-972.	2.8	10
18	Unlike PPAR γ , neither other PPARs nor PGC-1 α is elevated in the cerebrospinal fluid of patients with multiple sclerosis. <i>Neuroscience Letters</i> , 2017, 651, 128-133.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Non-motor Behavioral Alterations of PGC-1 β -Deficient Mice – A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 180.	2.0	9
20	Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene. <i>Frontiers in Neurology</i> , 2020, 11, 767.	2.4	9
21	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 373-392.	2.6	7
22	High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. <i>Acta Neurobiologiae Experimentalis</i> , 2016, 76, 176-181.	0.7	7
23	B7 Costimulation and Intracellular Indoleamine 2,3-Dioxygenase Expression in Umbilical Cord Blood and Adult Peripheral Blood. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1659-1665.	2.0	6
24	Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. <i>Ideggyógyászati Szemle</i> , 2013, 66, 407-14.	0.7	2
25	A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report. <i>Folia Neuropathologica</i> , 2020, 58, 377-385.	1.2	1
26	Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. <i>Ideggyógyászati Szemle</i> , 2019, 72, 39-47.	0.7	0